• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

    2/20/24 12:03:03 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email
    SC 13G/A 1 tm246474d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 4)*

     

    ELUTIA INC. 

    (Name of Issuer)

     

    Common Stock 

    (Title of Class of Securities)

     

    05479K106 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages 

    Page 1 of 9 Pages

     

     

     

     

    CUSIP NO. 05479K106 Page 2 of 9 Pages

     

    CUSIP No. 05479K106
    (1) Names of reporting persons Birchview Capital, LP
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization DE
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power

    1,655,184*

    (7) Sole dispositive power 0
    (8) Shared dispositive power

    1,655,184*

    (9) Aggregate amount beneficially owned by each reporting person

    1,655,184*

    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9)

    8.76%†

    (12) Type of reporting person (see instructions) IA

     

     

    * Birchview Capital, LP is the investment manager of Birchview Fund LLC (the “Fund”) which holds the shares referred to above. As a result, Birchview Capital, LP possesses the power to vote and dispose or direct the disposition of all the shares owned by the Fund. Mr. Strobeck, the Managing Member of Birchview Capital GP, LLC, the general partner of Birchview Capital, LP, has ownership of 283,018 shares held in separately managed accounts (“SMA”) managed by Birchview Capital, LP. Of the total 352,079 shares held in SMAs, Matthew Strobeck personally owns 165,094 shares and holds 117,924 shares in custodial accounts in his name. The remaining 69,061 shares are held in SMAs advised by Birchview Capital, LP, for the benefit of other investors.

     

    † Based on a total of 18,884,146 Class A shares outstanding of the Issuer as of November 9, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed November 14, 2023.

     

     

     

    CUSIP NO. 05479K106 Page 3 of 9 Pages

     

    CUSIP No.  05479K106
    (1) Names of reporting persons Birchview Fund LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization DE
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power

    1,303,105

    (7) Sole dispositive power 0
    (8) Shared dispositive power

    1,303,105

    (9) Aggregate amount beneficially owned by each reporting person

    1,303,105

    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9)

    6.9% †

    (12) Type of reporting person (see instructions) PN

     

     

    † Based on a total of 18,884,146 Class A shares outstanding of the Issuer as of November 9, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed November 14, 2023.

     

     

     

    CUSIP NO. 05479K106 Page 4 of 9 Pages

     

    CUSIP No.  05479K106
    (1) Names of reporting persons Matthew Strobeck
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization United States of America
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power

    1,655,184*

    (7) Sole dispositive power 0
    (8) Shared dispositive power

    1,655,184*

    (9) Aggregate amount beneficially owned by each reporting person

    1,655,184

    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9)

    8.76%†

    (12) Type of reporting person (see instructions) IN

     

     

    * Mr. Strobeck is the Managing Member of Birchview Capital GP, LLC, who is the General Partner of Birchview Capital, LP. As a result, Mr. Strobeck possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by Birchview Capital, LP the investment manager to the Fund. Mr. Strobeck disclaims beneficial ownership of any of the shares held by the Fund. Mr. Strobeck has ownership of 283,018 shares held in SMAs managed by Birchview Capital, LP. Of the total 352,079 shares held in SMAs, Matthew Strobeck personally owns 165,094 shares and holds 117,924 shares in custodial accounts in his name. The remaining 69,061 shares are held in SMAs advised by Birchview Capital, LP, for the benefit of other investors.

     

    † Based on a total of 18,884,146 Class A shares outstanding of the Issuer as of November 9, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed November 14, 2023.

     

     

     

    CUSIP NO. 05479K106 Page 5 of 9 Pages

     

    Item 1(a). Name of Issuer:
       
      ELUTIA INC. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
     

    12510 Prosperity Drive, Suite 370

    Silver Spring, MD 20904

       
    Item 2(a). Name of Person Filing
       
     

    The names of the person filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are:

     

    ·         Birchview Capital, LP

    ·         Birchview Fund LLC

    ·         Matthew Strobeck

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      688 Pine Street, 2nd Floor, Burlington, VT 05401

     

    Item 2(c). Citizenship:
       
      Birchview Capital, LP is a Delaware limited Partnership. Birchview Fund LLC is a Delaware limited liability company. Matthew Strobeck is a citizen of the United States.
       
    Item 2(d).

    Title of Class of Securities:

       
     

    Common Stock (the “Shares”)

       
    Item 2(e). CUSIP Number:
     

     

    05479K106

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);Page 5 of 6 pages

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J)

     

     

     

    CUSIP NO. 05479K106 Page 6 of 9 Pages

     

    Item 4.

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    Aggregate of all Reporting Persons: 1,655,184

    Birchview Capital, LP – 1,655,184

    Birchview Fund LLC – 1,303,105

    Matthew Strobeck – 1,655,184*

       
    Item 4(b).

    Percent of Class:

     

    Aggregate of all Reporting Persons: 8.76%

    Birchview Capital, LP – 8.76%

    Birchview Fund LLC – 6.9%

    Matthew Strobeck – 8.76%* 

       
    Item 4(c).

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or direct the vote:

    Birchview Capital, LP – 0

    Birchview Fund LLC – 0

    Matthew Strobeck – 0

     

      (ii)

    Shared power to vote or to direct the vote:

    Birchview Capital, LP – 1,655,184

    Birchview Fund LLC – 1,303,105

    Matthew Strobeck – 1,655,184

     

      (iii)

    Sole power to dispose or to direct the disposition of

    Birchview Capital, LP – 0

    Birchview Fund LLC – 0

    Matthew Strobeck – 0

     

      (iv)

    Shared power to dispose or to direct the disposition of

    Birchview Capital, LP – 1,655,184

    Birchview Fund LLC – 1,303,105

    Matthew Strobeck – 1,655,184 

     

    *Mr. Strobeck is the Managing Member of Birchview Capital GP, LLC, the General Partner of Birchview Capital, LP. As a result, Mr. Strobeck possesses the power to vote and dispose or direct the disposition of all the shares beneficially owned by Birchview Capital, LP as investment manager to the Fund. Mr. Strobeck disclaims beneficial ownership of any of the shares held by the Fund.

     

     

     

    CUSIP NO. 05479K106 Page 7 of 9 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
     

    This statement is being filed to report the fact that as of the date hereof each of the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities.

       

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person:

       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      This Item 7 is not applicable.
       
    Item 8. Identification and Classification of Members of the Group:
       
      See Exhibit A.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
      By signing below the Reporting Persons certifies that, to the best of such person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

    CUSIP NO. 05479K106 Page 8 of 9 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

    Birchview Capital, LP

     

    By:/s/ Matthew Strobeck  
      Matthew Strobeck, Managing Member of Birchview Capital GP, LLC, General Partner of Birchview Capital, LP  

     

    Birchview Fund LLC

     

    By:/s/ Matthew Strobeck  
      Matthew Strobeck, Managing Member of Birchview Partners LLC, Manager of Birchview Fund LLC  

     

    /s/ Matthew Strobeck  

    Matthew Strobeck

     

     

     

    CUSIP NO. 05479K106 Page 9 of 9 Pages

     

    EXHIBIT A

     

    Joint Filing Agreement

     

    The Undersigned agree that the statements on Schedule 13G with respect to the common stock of Elutia Inc. dated as of February 14, 2024, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    Date: February 14, 2024
     
    Signature: /s/ Matthew Strobeck  
    Name: Matthew Strobeck  

     

     
    Birchview Fund LLC
     
    By: /s/ Matthew Strobeck  
    Name: Matthew Strobeck  
    Title: Managing Member of Birchview Partners LLC, Manager of Birchview Fund LLC  
     
    Birchview Capital, LP
       
    By: /s/ Matthew Strobeck  
    Name: Matthew Strobeck  
    Title: Managing Member of Birchview Capital GP, LLC, General Partner of Birchview Capital, LP  

     

     

     

     

    Get the next $ELUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

      - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbreaking solution for cardiac implantable electronic device (CIED) procedures. Business Highlights: The EluPro™ Revolution is Now Underway: In its first full quarter post-launch, EluPro e

      5/8/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

      Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment. Elutia has appointed Dwayne Montgomery as Head of Cardiovascular to lead this newly establish

      5/1/25 4:05:06 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Financials

    Live finance-specific insights

    See more
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

      SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled

      2/20/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

      Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

      11/14/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

      4/A - ELUTIA INC. (0001708527) (Issuer)

      2/20/24 12:27:11 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elutia Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      10/15/24 6:59:31 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/20/24 12:03:03 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 30,287 shares and covered exercise/tax liability with 12,413 shares, increasing direct ownership by 7% to 342,378 units (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/11/25 5:54:33 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

      SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:49:05 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Elutia Inc.

      SCHEDULE 13G - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:25:26 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Elutia Inc.

      10-Q - ELUTIA INC. (0001708527) (Filer)

      5/13/25 4:50:30 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    See more
    • Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

      SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

      7/31/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care